RxDoctor Payments Data

Carlos Delgado, MD

General Practice · Hialeah, FLNPI 1922065218

Payments from drug & device makers

$525in general payments, 2019–2025

Across 12 payments — averaging $43.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$146
  • W. L. Gore & Associates, Inc.$128
  • Abbott$81
  • Novo Nordisk$73
  • PBG Puerto Rico LLC$43
  • Lilly USA, LLC$19
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$525100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic1$146
W. L. Gore & Associates, Inc.1$128
Abbott1$81
Novo Nordisk4$73
PBG Puerto Rico LLC2$43
Lilly USA, LLC1$19
Amgen1$18
Pfizer1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$525 in reported general payments places this provider in the 65th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$51,178
Medicare patients
86
Services billed
507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide15$12,943
FarxigaDapagliflozin Propanediol14$8,137
VascepaIcosapent Ethyl22$7,461
LinzessLinaclotide13$7,273
Lactulose233$6,807
Levothyroxine Sodium125$1,717
Atorvastatin Calcium119$1,573
Desmopressin Acetate30$1,436
Potassium Chloride79$1,339
Omeprazole97$1,009
Simvastatin102$917
FenofibrateFenofibrate Nanocrystallized12$823
Lisinopril95$773
Metformin Hcl81$729
Valsartan22$651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$73$12,94315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,901 general practice providers in Florida.

Other general practice in Hialeah

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →